# Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

> **NCT01363401** · PHASE1,PHASE2 · COMPLETED · sponsor: **Corestemchemon, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **BIOLOGICAL:** HYNR-CS inj
- **OTHER:** Control group

## Key facts

- **NCT ID:** NCT01363401
- **Lead sponsor:** Corestemchemon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-05
- **Final completion:** 2013-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363401, "Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01363401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*